GET DAILY SIGNALSNyxoah (NYXH) Stock Drops -32% as Guidance Is Lowered
Key Takeaways
- Nyxoah (NYXH) shares declined roughly 32% over the last 30 days, falling from about $1.31 to near $0.89.
- The selloff was driven primarily by a cut to full-year 2026 revenue guidance, announced alongside preliminary third-quarter results.
- Third-quarter global net revenue reached approximately €9.2 million (up 19% sequentially), with U.S. revenue up 29% sequentially, but 2026 guidance was lowered to €33–35 million from €36–40 million.
- Positive ACCCESS pivotal data and an FDA PMA supplement to expand Genio's U.S. indication were largely overshadowed by the guidance reset.
- Several analysts trimmed price targets, including Cantor Fitzgerald (from $6 to $3) and Stifel (from $5 to $3).
- Over the last quarter, the stock fell roughly 44%, extending a broader multi-month downtrend.
Company Overview for Nyxoah (NYXH)
Nyxoah SA is a Belgian medical technology company headquartered in Mont-Saint-Guibert that develops and commercializes neuromodulation-based treatments for obstructive sleep apnea (OSA). Its lead product, the Genio system, is a leadless, battery-free hypoglossal nerve stimulation (HGNS) therapy designed as an alternative to continuous positive airway pressure (CPAP) and to bulkier implanted stimulation devices.
Genio received European CE marking in 2019 and U.S. Food and Drug Administration (FDA) approval in August 2025 for OSA patients. Nyxoah is also pursuing expansion into Complete Concentric Collapse (CCC) patients, a population for which competing therapies are often contraindicated. The company completed dual listings on Euronext Brussels and the Nasdaq, and investors follow the stock closely for its U.S. commercial ramp, clinical and regulatory milestones, and cash runway.
Recent Stock Price Performance for NYXH
Over the last 30 days, NYXH fell approximately 32%, declining from a closing price near $1.31 in early-to-mid October to about $0.89 in the latest session. The sharpest leg lower occurred in mid-to-late October, when the shares broke decisively below the $1.00 level amid heavy volume. I also checked this using Tickeron’s AI Pattern Search Engine to confirm the strength of the move.
The quarterly trend has been even steeper. Over the past three months, the stock declined roughly 44%, from around $1.59 in mid-August to current levels. This continues a longer downtrend in which the shares have traded well below their 52-week high and near the lower end of their 52-week range, reflecting persistent investor concerns about growth trajectory, profitability, and dilution risk.
Key Drivers Behind the 30-Day Decline
The primary catalyst for the recent decline was Nyxoah's announcement of preliminary third-quarter 2026 results on October 19, 2026. The company reported global net revenue of approximately €9.2 million, up 19% sequentially, with U.S. net revenue of roughly €6.7 million, up 29% sequentially. However, management lowered full-year 2026 revenue guidance to €33–35 million, down from a prior range of €36–40 million, citing a U.S. sales ramp that was progressing more gradually than initially expected.
The guidance cut overshadowed otherwise encouraging clinical news. Nyxoah reported that its ACCCESS U.S. pivotal study met its co-primary efficacy and safety endpoints in Complete Concentric Collapse patients, with a 12-month AHI responder rate of 77.2% and no device- or procedure-related serious adverse events. The company also submitted a premarket approval (PMA) supplement to the FDA to expand Genio's U.S. indication to CCC patients under Breakthrough Device Designation.
Analyst actions added further pressure. Cantor Fitzgerald lowered its price target from $6 to $3 while maintaining an Overweight rating, and Stifel reduced its target from $5 to $3 with a Hold rating. These revisions, combined with the reduced revenue outlook, reinforced a more cautious near-term view of the company's commercial execution and funding needs.
Factors Influencing Performance Over the Quarter
Over the last quarter, NYXH's decline reflected a combination of execution concerns and management transition. The company experienced a CFO change in September, naming former CFO Loïc Moreau as interim finance chief, and appointed Liam Kelly as Chief Executive Officer in late September. These leadership shifts coincided with investor unease about the pace of the U.S. commercial launch.
Although the company reported roughly €77 million in cash, cash equivalents, and financial assets as of September 30, 2026, the stock's sustained weakness signals ongoing questions about the path to profitability, cash burn, and the potential for future capital raises. The downward trajectory has outweighed the positive clinical momentum from the ACCCESS study and the broader story of a differentiated, patient-friendly hypoglossal nerve stimulation option.
Outlook and Factors to Monitor
Looking ahead, the key factors to monitor include Nyxoah's full third-quarter financial results and any commentary on fourth-quarter U.S. growth, which management has said it expects to improve relative to the third quarter. The FDA's review of the PMA supplement to expand Genio's indication to CCC patients represents a significant regulatory catalyst.
Investors will also watch analyst revisions, cash-burn trends relative to the company's reported liquidity, and any indications of a future capital raise. Competitive dynamics in the hypoglossal nerve stimulation market, reimbursement and prior-authorization trends, and the pace of surgeon training and account activations in the U.S. will remain important demand indicators. Macroeconomic factors affecting small-cap and pre-profit healthcare names may also continue to influence sentiment. From what I see, the regulatory and commercial execution updates will be particularly telling in the months ahead.
Exploring AI-Driven Trading Approaches
In my own research process, I frequently review Tickeron’s AI tools to gain additional perspective on market movements and strategy options. Their AI Trading Bots offer a range of automated approaches with varying timeframes and performance metrics, allowing users to compare results across different conditions. The Trending AI Robots section highlights some of the stronger performers at any given time, which can be useful when evaluating systematic ideas alongside fundamental analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
NYXH's RSI Oscillator climbs out of oversold territory
The RSI Indicator for NYXH moved out of oversold territory on November 06, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 38 of the 44 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 71 cases where NYXH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on NYXH as a result. In 60 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
The Moving Average Convergence Divergence (MACD) for NYXH just turned positive on November 03, 2026. Looking at past instances where NYXH's MACD turned positive, the stock continued to rise in 32 of 49 cases over the following month. The odds of a continued upward trend are 65%.
Following a +6.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where NYXH advanced for three days, in 144 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
NYXH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NYXH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for NYXH entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.036) is normal, around the industry mean (4.142). P/E Ratio (-0.386) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.746) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. NYXH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NYXH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement